Clinical trial
A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma.
NCT00618982 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma.
- Lead sponsor
- Bayer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 29, 2008
- Completion date
- January 31, 2011
- Enrollment
- 83 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.